Nathanael S. Gray, PhD (Damon Runyon-Rachleff Innovator ‘08-‘10), Matthew Meyerson, MD, PhD (Damon Runyon Fellow ‘95-‘98) and colleagues at Dana-Farber Cancer Institute, Boston, reported that the gene FGFR1 is amplified in 21% of squamous cell lung cancers. In cell lines, inhibition of FGFR blocked cell growth. These findings suggest that FGFR may be a promising therapeutic target for these lung cancers. The report was published in the journal PLoS ONE.